Selincro

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
PSUSA/10120 /201802	Periodic Safety Update EU Single assessment - nalmefene	20/09/2018	20/11/2018	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10120/201802.
PSUSA/10120 /201702	Periodic Safety Update EU Single assessment - nalmefene	12/10/2017	08/12/2017	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10120/201702.
R/0022	Renewal of the marketing authorisation.	14/09/2017	10/11/2017	SmPC, Labelling and	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Selincro in the approved indication remains favourable and therefore

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

				PL	recommended the renewal of the marketing authorisation with unlimited validity.
II/0020/G	This was an application for a group of variations. Update of section 4.7 of the SmPC to add new information regarding effects on ability to drive and use machines, based on clinical study and post-marketing data. Update of section 4.8 of the SmPC in order to add the adverse drug reaction “diarrhoea” with frequency “common”, based on clinical study and post-marketing data. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	06/07/2017	10/11/2017	SmPC and PL	Based on clinical study and post-marketing data related to road traffic accidents and taking into account the known adverse reactions of Selincro potentially affecting attention (feeling abnormal, nausea, dizziness, somnolence, insomnia, headache and disturbance in attention), the CHMP considered that Selincro may have minor to moderate influence on the ability to drive and use machines and that patients should exercise caution particularly when starting treatment. Considering the pharmacological actions of Selincro as well as the available clinical study and post-marketing data, diarrhoea was included in the tabulated list of adverse reactions as a common adverse reaction.
PSUSA/10120 /201602	Periodic Safety Update EU Single assessment - nalmefene	15/09/2016	18/11/2016	PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)’ for PSUSA/10120/201602.
IB/0019	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	10/11/2016	n/a		

IA/0018/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	29/07/2016	n/a		
II/0015	Update of section 5.2 of the SmPC in order to update the pharmacokinetic properties in case of renal impairment. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 9.1 and to correct some minor linguistic errors. In addition the Labelling text has been updated according to comments received from the EMA Labelling Review and Standards Office in connection with the review of specimens for variation EMEA/H/C/002583/0011&0012. In addition, the MAH took the occasion to update	28/01/2016	18/11/2016	SmPC, Annex II, Labelling and PL	Administration of a single oral dose of nalmefene 18.06 mg to patients with mild, moderate or severe renal impairment, classified using the estimated glomerular filtration rate, resulted in an increased exposure to nalmefene relative to that in healthy subjects. For patients with mild, moderate or severe renal impairment the AUC for nalmefene was 1.1 times, 1.4 times and 2.4 times higher, respectively. Further, the Cmax and elimination half-life for nalmefene was up to 1.6 times higher in patients with severe renal impairment. No clinically relevant changes were seen in tmax for any of the groups. For the inactive major metabolite nalmefene 3-O-glucuronide, the AUC and Cmax were up to 5.1 times

	information regarding the local representative for Austria, Iceland and Sweden in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				and 1.8 times higher in patients with severe renal impairment, respectively (see sections 4.3 and 4.4).
IB/0016	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	02/12/2015	n/a		
PSUSA/10120 /201502	Periodic Safety Update EU Single assessment - nalmefene	10/09/2015	n/a		PRAC Recommendation - maintenance
PSUSA/10120 /201408	Periodic Safety Update EU Single assessment - nalmefene	26/03/2015	27/05/2015	SmPC	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10120/201408.
IB/0013/G	This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	22/04/2015	n/a		
IAIN/0012	B.II.e.5.a.1 - Change in pack size of the finished	19/12/2014	27/05/2015	SmPC,	

	product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes			Labelling and PL	
IAIN/0011/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	19/12/2014	27/05/2015	SmPC, Labelling and PL	
PSUV/0009	Periodic Safety Update	11/09/2014	n/a		PRAC Recommendation - maintenance
II/0005/G	This was an application for a group of variations. Addition of a new alternative manufacturer of a key intermediate using an alternative starting material. Minor changes to the manufacturing process of the active substance. B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	25/04/2014	n/a		

PSUV/0008	Periodic Safety Update	06/03/2014	n/a		PRAC Recommendation - maintenance
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/12/2013	22/05/2014	PL	
IAIN/0006	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	07/11/2013	n/a		
IA/0004	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	27/09/2013	22/05/2014	SmPC and PL	
IB/0003/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	24/07/2013	22/05/2014	SmPC	
IAIN/0002/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.	30/05/2013	22/05/2014	SmPC, Labelling and PL	

	tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes				
IB/0001/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place	17/04/2013	n/a		